Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RADX Radiopharm Theranostics Limited | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $1.62 +6.6% | $16.31 +6.3% |
| StockIQ Score | 46D+ Moderate Risk: High | 42D Weak Risk: Medium |
| Technical | 22F | 36F |
| Fundamental | 22F | 35F |
| Growth | 74B | 50C- |
| Fair Value | 50C- | 38F |
| News | 92A+ | 50C- |
| Quality | 58C | 50C- |
| Risk | 40D | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Radiopharm Theranostics (RADX) outperforms Ascentage Pharma (AAPG) in growth (74 vs. 50) and valuation (50 vs. 38), showing stronger potential for expansion and pricing relative to earnings. However, AAPG has a slightly higher technical score (36 vs. 22) and better fundamental stability (35 vs. 22). RADX’s moderate rating contrasts with AAPG’s weak rating, indicating more confidence in its overall performance.
